Certara (CERT) Stock Price & Analysis
CERT Stock Chart & Stats
- Day’s Range
- MXN 173.28 - MXN 173.28
- 52-Week Range
- MXN 173.28 - MXN 219.68
- Previous Close
- MXN 173.28
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- MXN 31.59B
- Enterprise Value
- MXN 1.13B
- Total Cash (Recent Filing)
- MXN 184.14M
- Total Debt (Recent Filing)
- MXN 291.84M
- Price to Earnings (P/E)
- ―
- Beta
- 0.03
- Next Earnings
- Nov 05, 2026 (Est.)
- EPS Estimate
- 1.63
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Software Momentum
Software is becoming a larger portion of Certara’s business while bookings continue to grow, supporting a more recurring and scalable revenue mix. This shift can improve customer retention, operating leverage, and visibility as adoption of drug-development platforms expands.
Cash Generation And Liquidity
Consistently positive free cash flow gives Certara internal funding capacity even while net income remains negative. Combined with low leverage and substantial cash, this supports investment in products, resilience through slower demand, and reduced reliance on external financing.
AI And Scientific Leadership
Deep scientific expertise and accelerating AI adoption can strengthen Certara’s differentiation in model-informed drug development. Faster development and service workflows may improve customer value, support innovation, and create durable efficiency benefits across its software and consulting offerings.
Bears Say
Services Weakness
Weak services revenue and bookings create a meaningful drag because services remain a large part of Certara’s business. The ongoing go-to-market reorganization adds execution risk, and recovery depends on converting the pipeline into revenue without further disruption.
Limited Growth And Margin Pressure
Low projected revenue growth indicates that Certara’s overall expansion is not yet matching its software momentum. The reduced margin outlook also suggests that divestiture-related stranded costs and operating pressures may limit near-term earnings conversion and investment flexibility.
Persistent Unprofitability
Certara’s healthy gross margin and cash generation have not yet translated into consistent bottom-line profits. Continued net losses can constrain returns on its sizable equity base, reduce financial flexibility over time, and increase dependence on successful cost and growth initiatives.
Certara News
CERT FAQ
What was Certara’s price range in the past 12 months?
What is Certara’s market cap?
When is Certara’s upcoming earnings report date?
How were Certara’s earnings last quarter?
Is Certara overvalued?
Does Certara pay dividends?
What is Certara’s EPS estimate?
How many shares outstanding does Certara have?
What happened to Certara’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Certara?
What is the TipRanks Smart Score and how is it calculated?
Certara Stock Smart Score
Company Description
Certara
Certara, Inc. provides advanced software solutions and technology-driven services, specializing in biosimulation throughout the entire drug development lifecycle. From initial drug discovery and preclinical research to clinical trials, regulatory submissions, and market entry, the company's core mission is to accelerate the delivery of new medicines to patients by transforming these processes with its innovative biosimulation software and expertise. Its extensive portfolio of technology-enabled services includes mechanistic and empirical biosimulation, strategic guidance for drug development and regulatory affairs, clinical pharmacology, model-based meta-analysis, specialized regulatory writing and medical communications, regulatory operations support, and market access consultation. Furthermore, Certara offers a robust suite of software platforms covering mechanistic and empirical PK/PD biosimulation, data standardization and compliance, scientific informatics, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions, and market access communication. The company's clientele primarily comprises biopharmaceutical firms, academic institutions, and governmental organizations. Established in 2008 and headquartered in Princeton, New Jersey, Certara maintains a significant global presence, with operations spanning numerous countries including the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Jon Resnick
- Employees
- 1,546
- Website
- www.certara.com
- Address
- 4 Radnor Corporate Center, Radnor, PA, 19087, US
Certara (CERT) Earnings & Revenues
CERT Company Deck
CERT Earnings Call
Earnings Call SentimentNeutral
The call presented a balanced picture: clear, measurable momentum in software, AI integration and product/scientific leadership (strong bookings growth in software, pipeline expansion, cloud wins, regulatory engagement and scientific publications), alongside near-term financial and operational headwinds (service revenue declines, modest overall revenue growth, margin impact from divestiture-related stranded costs, and a GAAP net loss). Management has taken decisive operational actions (RIF, product reprioritization, new CCO, $13M run-rate savings) and is bullish on mid-term growth, but execution risk remains in converting a larger services pipeline and realizing cost savings. On balance the results are cautiously constructive but not yet a decisive turnaround in overall financial performance.
View all MX:CERT earnings summariesCERT Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 1 | 13 |
| Technical Analysis | 2 | 1 | 2 |
| Moving Averages | 1 | 0 | 11 |
